Holen Sie sich die Stockscreener-App
1.62
9.46%
0.14
Alx Oncology Holdings Inc Aktie (ALXO) Neueste Nachrichten
ALX Oncology’s (ALXO) Overweight Rating Reiterated at Cantor Fitzgerald - Defense World
ALX Oncology’s (ALXO) “Buy” Rating Reiterated at HC Wainwright - Defense World
Alx Oncology Holdings Inc (ALXO) Is On The Launchpad, Waiting For Long-Term Buyers. - Stocks Register
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Shares Sold by Charles Schwab Investment Management Inc. - Defense World
ALX Oncology stock falls on Jefferies downgrade (ALXO:NASDAQ) - Seeking Alpha
Alx Oncology shares down in pre-market as Jefferies downgrades stock to 'hold' - Investing.com Canada
Jefferies Financial Group Downgrades ALX Oncology (NASDAQ:ALXO) to Hold - MarketBeat
Early-Onset Cancer Trends Spark Interest in Promising Oncology Pipelines - Baystreet.ca
ALX Oncology (NASDAQ:ALXO) Earns "Overweight" Rating from Cantor Fitzgerald - MarketBeat
HC Wainwright Reiterates Buy Rating for ALX Oncology (NASDAQ:ALXO) - MarketBeat
ALX Oncology to Present Updated Results from Phase 2 - GlobeNewswire
ALX Oncology to Present Key Phase 2 Gastric Cancer Trial Data at ASCO GI 2025 Symposium - StockTitan
ALX Oncology Highlights Promising Trial Results - MSN
ALX Oncology to Host Webcast on December 17 Featuring Phase 1b/2 Trial Data for Evorpacept in Metastatic Breast Cancer - Nasdaq
ALX Oncology to Host Virtual Company Event Highlighting New Clinical Data Presented at SABCS 2024 - The Manila Times
ALX Oncology Sets Key Data Review: Evorpacept Breast Cancer Trial Results From SABCS 2024 - StockTitan
Fmr LLC Sells 1,949,890 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) - MarketBeat
ALX Oncology Announces New Data Demonstrating Evorpacept in - GlobeNewswire
ALX Oncology's Evorpacept Shows 55.6% Response Rate in HER2+ Breast Cancer Trial - StockTitan
ALXO (ALX Oncology Holdings) Enterprise Value : $-43.27 Mil (As of Dec. 07, 2024) - GuruFocus.com
Insider Buying: Rekha Hemrajani Acquires 30,000 Shares of ALX On - GuruFocus.com
ALXO (ALX Oncology Holdings) Price-to-Operating-Cash-Flow : (As of Dec. 03, 2024) - GuruFocus.com
ALX Oncology shares jump 9% after Jefferies upgrade - MSN
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives $12.50 Average Target Price from Brokerages - Defense World
Brokerages Set ALX Oncology Holdings Inc. (NASDAQ:ALXO) PT at $12.50 - Defense World
Financial Review: Inventiva (NASDAQ:IVA) & ALX Oncology (NASDAQ:ALXO) - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Receives Consensus Rating of "Moderate Buy" from Analysts - MarketBeat
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Given Average Recommendation of "Moderate Buy" by Brokerages - MarketBeat
3 US Penny Stocks With Market Caps Over $30M To Consider - Simply Wall St
ALX Oncology to Participate in the Piper Sandler 36th Annual Healthcare Conference - GlobeNewswire
ALX Oncology CEO to Present at Piper Sandler Healthcare Conference | ALXO Stock News - StockTitan
GSA Capital Partners LLP Invests $88,000 in ALX Oncology Holdings Inc. (NASDAQ:ALXO) - Defense World
Contrasting ALX Oncology (NASDAQ:ALXO) & Viracta Therapeutics (NASDAQ:VIRX) - Defense World
ALX Oncology Holdings (ALXO) Loses -27.11% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner - Yahoo Finance
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Short Interest Update - Defense World
ALX Oncology FY2024 EPS Forecast Raised by Cantor Fitzgerald - Defense World
ALX Oncology Holdings Inc. (NASDAQ:ALXO) Sees Significant Decrease in Short Interest - MarketBeat
Brokers Set Expectations for ALX Oncology FY2024 Earnings - MarketBeat
Former Mirati CMO Alan Sandler joins ALX Oncology - The Pharma Letter
Data-Based Insights About XBP Europe Holdings Inc (XBP) - Stocks Register
New Outlook On Celsius Holdings Inc - Stocks Register
ALX Oncology Strengthens Leadership with Key Appointment - TipRanks
ALX Oncology Appoints Alan Sandler, M.D., as Chief Medical Officer - NRToday.com
ALX Oncology Appoints Former Mirati & Genentech Exec as Chief Medical Officer | ALXO Stock News - StockTitan
ALX Oncology Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024 - Marketscreener.com
Cantor Fitzgerald Reiterates Overweight Rating for ALX Oncology (NASDAQ:ALXO) - Defense World
ALXO stock touches 52-week low at $1.31 amid market challenges - Investing.com
FMR LLC's Strategic Reduction in ALX Oncology Holdings Inc Shares - GuruFocus.com
ALX Oncology's (ALXO) Overweight Rating Reaffirmed at Cantor Fitzgerald - MarketBeat
Brokers Issue Forecasts for ALX Oncology FY2028 Earnings - MarketBeat
ALX Oncology Reports Third Quarter 2024 Financial Results and Provides Corporate Update - GlobeNewswire
ALX Oncology Announces November Investor Conference Participation - GlobeNewswire
2.88%
2.65%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):